{"url_path":"/sec/tngx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-221656-index.html","accession_number":"0001193125-26-221656","cik":"0001819133","ticker":"TNGX","issuer_name":"Tango Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-221656-index.html","primary_entity_key":"0001819133","primary_entity_name":"Tango Therapeutics, Inc."},"word_count":543,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Second Amended and Restated Certificate of Incorporation of Tango Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 10-Q filed with the SEC on August 7, 2024).](https://www.sec.gov/Archives/edgar/data/1819133/000095017024092274/tngx-ex3_1.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of Tango Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s registration statement on Form S-8 filed with the SEC on October 14, 2021).](https://www.sec.gov/Archives/edgar/data/1819133/000119312521298942/d211731dex42.htm)\n\n3.3\n\n \n\n[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the SEC on June 6, 2025)](https://www.sec.gov/Archives/edgar/data/1819133/000119312525137032/d926935dex31.htm).\n\n10.1*#\n\n \n\n[Amended and Restated Non-Employee Director Compensation Policy.](tngx-ex10_1.htm)\n\n10.2#\n\n \n\n[Amended and Restated Employment Agreement, dated as of January 8, 2026 by and between the Company and Barbara Weber (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1819133/000119312526007086/d26323dex101.htm)\n\n10.3#\n\n \n\n[Employment Agreement, dated as of January 8, 2026 by and between the Company and Malte Peters (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by the Registrant on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1819133/000119312526007086/d26323dex103.htm)\n\n10.4#\n\n \n\n[Employment Agreement, dated as of April 15, 2026 by and between the Company and Matthew Gall (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on April 15, 2026).](https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/d144586dex101.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tngx-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](tngx-ex31_2.htm)\n\n32.1**\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tngx-ex32_1.htm)\n\n32.2**\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tngx-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104*\n\n \n\nCover Page Interactive Data File (formatted in as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)\n\n \n\n* Filed herewith.\n\n** The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by\n\n29\n\n \n\nreference.\n\n# Indicates a management contract or any compensatory plan, contract or arrangement.\n\n \n\n \n\n \n\n30\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nTango Therapeutics, Inc.\n\nDated: May 13, 2026\n\nBy:\n\n/s/ Malte Peters\n\nMalte Peters, MD\n\nPresident and Chief Executive Officer\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\nTango Therapeutics, Inc.\n\n \n\nBy:\n\n/s/ Matthew Gall\n\nMatthew Gall\n\nChief Financial Officer\n\n \n\n(Principal Financial Officer)\n\n \n\n31"}